Fig. 3.

GOLM1 deficiency in IEC increases mouse susceptibility of colitis and CAC. a The body weights of 2% DSS-treated Golm1^−ΔIEC mice and Golm1^−flox/flox counterparts were recorded on indicated days (the data are represented as the means ± SEM, n = 5; *P < 0.05). b The disease activity indexes of Golm1^−ΔIEC mice and Golm1^−flox/flox counterparts administered 2% DSS for 5 days (the data are represented as the means ± SEM, n = 5; *P < 0.05, **P < 0.01, ***P < 0.001). c Representative image of colons obtained from Golm1^−ΔIEC mice and Golm1^−flox/flox counterparts treated with 2% DSS for 5 days and sacrificed on day 8. d Representative H&E staining of mouse colon sections obtained from DSS-treated mice on the indicated days. Scale bars, 100 μm. e Representative Ki67 staining of colon sections from mice treated with 2% DSS and sacrificed on the indicated days. Scale bars, 100 μm. Quantification is shown in the histogram (the data are represented as the means ± SEM, n = 5; *P < 0.05; unpaired, two-tailed Student’s t test). f Representative images of colon tumors obtained from AOM/DSS-treated mice. g Representative H&E staining of mouse colon sections obtained from AOM/DSS-treated mice. Upper scale bars, 500 μm; lower scale bars, 50 μm. Percentages of mice with dysplasia at 70 days after injection of AOM. h Representative image of the spleens obtained from AOM/DSS-treated mice